Among patients with thymic epithelial tumors and NSCLC undergoing PD-1 therapy, peripheral blood PD-1+CD8+ T cells (Ki-67D7/D0) exhibited a proliferative response within the initial week of treatment, enabling the differentiation between response to therapy and disease progression. Here, PDCD1 is linked to non-small cell lung carcinoma.